Zane Saul, MD
Infectious Disease · Stratford, CTNPI 1023089513
Payments from drug & device makers
Across 1,397 payments — averaging $367.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$247K
- Viiv Healthcare Company$144K
- Pfizer$78K
- Merck$19K
- Insmed, Inc.$13K
- Melinta Therapeutics, LLC$3K
- plus $9K from 31 others
What the payments were for
- Consulting fees$20,1354%
- Speaking & faculty fees$440,88386%
- Travel & lodging$23,3535%
- Food & beverage$27,8225%
- Education$5480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 372 | $247,213 |
| Viiv Healthcare Company | 248 | $143,714 |
| Pfizer | 112 | $78,042 |
| Merck | 94 | $18,655 |
| Insmed, Inc. | 49 | $12,904 |
| Melinta Therapeutics, LLC | 18 | $3,232 |
| AbbVie(2 entities) | 94 | $1,680 |
| Johnson & Johnson(2 entities) | 74 | $918 |
| Cumberland Pharmaceuticals, Inc. | 74 | $794 |
| Theratechnologies Inc. | 25 | $605 |
| EMD Serono, Inc. | 24 | $525 |
| Lilly USA, LLC | 26 | $504 |
| AstraZeneca | 27 | $493 |
| Otsuka America Pharmaceutical, Inc. | 29 | $480 |
| Janssen Products, LP | 4 | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $319 |
| Paratek Pharmaceuticals, Inc. | 17 | $307 |
| Amgen | 13 | $247 |
| Boehringer Ingelheim | 13 | $244 |
| Exact Sciences | 10 | $231 |
| Astellas Pharma US Inc | 5 | $211 |
| Aimmune Therapeutics, Inc. | 4 | $178 |
| Novo Nordisk | 8 | $146 |
| CSL Behring | 5 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $122 |
| Ferring Pharmaceuticals Inc. | 5 | $106 |
| Cormedix Inc. | 4 | $73 |
| Eisai Inc. | 5 | $68 |
| Shionogi Inc | 2 | $53 |
| Nabriva Therapeutics, PLC | 4 | $51 |
| GSK | 2 | $43 |
| Janssen Scientific Affairs, LLC | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$512,741 in reported general payments places this provider in the 95th percentile of 159 infectious disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 235 | $1,042,683 |
| DovatoDolutegravir Sodium/Lamivudine | 89 | $272,523 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 44 | $222,962 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 37 | $140,029 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 27 | $114,240 |
| TivicayDolutegravir Sodium | 41 | $96,233 |
| MounjaroTirzepatide | 66 | $80,041 |
| JardianceEmpagliflozin | 76 | $74,327 |
| OzempicSemaglutide | 56 | $64,963 |
| IsentressRaltegravir Potassium | 22 | $62,781 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 161 | $49,486 |
| EliquisApixaban | 40 | $35,024 |
| PrezcobixDarunavir/Cobicistat | 13 | $31,443 |
| JanuviaSitagliptin Phosphate | 37 | $29,762 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $27,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $247,213 | $1,184,627274 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $143,714 | $368,756130 claims |
| Janssen Products, LPSymtuza | $324 | $222,96244 claims |
| MerckIsentress, Januvia | $18,655 | $92,54359 claims |
| Boehringer IngelheimJardiance, Tradjenta | $244 | $90,502100 claims |
| PfizerAbrysvo, Eliquis | $78,042 | $84,510201 claims |
| Lilly USA, LLCMounjaro | $504 | $80,04166 claims |
| Novo NordiskOzempic | $146 | $64,96356 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $918 | $46,45033 claims |
| AstraZenecaFarxiga | $493 | $18,76719 claims |
| AbbVieLinzess | $1,680 | $7,39813 claims |
| GSKShingrix | $43 | $3,80918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 infectious disease providers in Connecticut.
Other infectious disease in Stratford
- David LoboStratford$3K
- Goran MiljkovicStratford$2K
- Onyema OgbuaguNew Haven$10.9M
- Albert KoNew Haven$2M
- Michael ParryStamford$1.1M
- Paul NeeDanbury$817K
- Stephen ScholandMeriden$428K
- David RubinNorwalk$413K
- Elizabeth CooneyNew Haven$377K
- Steven SchnittmanWest Haven$363K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.